期刊文献+

生长抑素受体亚型SSTR2、SSTR3在淋巴瘤中的表达及临床意义(英文) 被引量:1

Expression and Clinical Significance of Somatostatin Receptor Subtype SSTR2,3 in Lymphoma
原文传递
导出
摘要 目的:探讨生长抑素受体亚型SSTR2和SSTR3在不同类型、不同部位淋巴瘤中的表达情况并分析其临床意义。方法:采用RT-PCR法检测105例4种不同淋巴瘤石蜡标本中SSTR2和SSTR3的基因表达情况。结果:SSTR2及SSTR3在粘膜相关性淋巴瘤阳性表达率分别为(8/27),(6/27),弥漫大B细胞型淋巴瘤(14/36)(,12/36),NK/T细胞淋巴瘤(9/22),(6/22),伯基特淋巴瘤(6/20),(7/20),SSTR2的总阳性率为(37/105),SSTR3的总阳性率为(31/105)。其中病变位于膈上的SSTR2的总阳性率为(24/105),膈下的总阳性率(14/105),而SSTR3在膈上的总阳性率为(19/105),膈下的为(11/105)。结论:部分淋巴瘤组织中至少表达一种生长抑素受体,且表达率较低,但淋巴瘤是对放射性敏感的肿瘤,低表达的生长抑素受体对淋巴瘤的诊断及靶向治疗方面是否有意义,还需要进一步研究。 Objective:To investigate the expression of somatostatin receptor subtypes SSTR2 and SSTR3 in different types,different parts of lymphoma.Methods:The expressions of SSTR2 and SSTR3 gene in 105 cases lymphoma paraffin-embedded specimens were detected by RT-PCR.Results:The positive expression rate of SSTR2 and SSTR3 in the mucosa-associated lymphoma was(8/27),(6/27),diffuse large B-cell lymphoma(14/36),(12/36),NK/T cells lymphoma(9/22),(6/22),and Burkitt's lymphoma(6/20),(7/20).The total positive expression rate of SSTR2 were(37/105),and SSTR3(31/105).In which the lesions in the diaphragm the total positive expression rate of SSTR2 and SSTR3 were(24/105),(19/105).The subdiaphragmatic total positive rate respectively(14/105),(11/105).Conclusion:We found that partial lymphoma at least express a somatostatin receptor of SSTR2,SSTR3,but the expression rates was low.However lymphomas are highly radiosensitive tumors whether low expression of somatostatin receptors in lymphoma is sufficient for diagnosis and targeting treatment in these tumors needs further study.
出处 《现代生物医学进展》 CAS 2012年第22期4351-4354,共4页 Progress in Modern Biomedicine
关键词 生长抑素 受体 淋巴瘤 RT-PCR Somatostatin Receptor Lymphoma RT-PCR
  • 相关文献

参考文献17

  • 1Dalm VA, Holland LJ, Mooy CM, et al. Somatostatin receptors in mal-ignant lymphomas: targets for radiotherapy[J]. J Nucl Med, 2004, 45(1):8-16.
  • 2Patel YC, Green Wood MT, Panetta R, et al. Minireview the somato- statain receptor family [J]. Life Sciences, 1995, 57 (13): 1249.
  • 3Israel O, Keidar Z, Bar-Shalom R. Posion emission tomography in the evaluation of lymphoma Semin[J]. NuclMed, 2004, 34(3): 166-179.
  • 4Friedberg JW, Chengazi VPET. scans in the staging of lymphoma: current status[J]. Oncologist, 2003, 8(5):438-447.
  • 5Filmont JE, Vranjesevic DQ. Conventional imaging and 2-deoxy--2 -- [18F]fluoro-D-glucose positron emission tomography for predicting t- he clinical outcome of previously a:eated non-Hodgkin's lymphoma oatientsrJ].Mol Imain Biol. 2003.5(4),232-239.
  • 6Delbeke D, Martin WH, Morgan DS, et al. 2-deoxy-2-[F-18] fluoro-D- glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma[J]. Mol Imaging Biol, 2002, 4(I): 105-114.
  • 7Hong SP, Hahn IS, Lee JD, et al. 18F-fluorodeoxyglucose-positron em- ission tomography in the staging of malignant lymphoma compared w- ith CT and 67Ga scan[J]. Yonsei Med J, 2003, 44(5):79-786.
  • 8Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography[J]. Blood, 1998, 91 (9): 3340-3346.
  • 9Lipp RW, Silly H, Ranner Q, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy[J]. J Nucl Med, 1995, 36(1): 13-18.
  • 10Raderer M, Traub T, Formanek M, et al. Somatostatin-receptor scinti- graphy for staging and follow-up of patients with extraintestinal mar- ginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT~-twe[J]. Br J Cancer. 2001.85(10):1462-1466.

同被引文献14

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部